{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-034949","form_type":"8-K","ticker":"AURX","cik":"0001091596","company_name":"Nuo Therapeutics, Inc.","filed_at":"2023-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.191893+00:00","generated_at":"2026-06-07T09:43:24.516928+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Nuo Therapeutics raises $962,500 in private placement of 1.925M shares at $0.50/share","bullets":["Sold 1,925,000 common shares at $0.50 each for gross proceeds of $962,500.","Proceeds will be used for working capital purposes.","Participants include director Scott Pittman ($300k), COO Clausen ($10k), and stockholder Sheedy ($75k).","Total shares outstanding after placement: 44,241,516.","Offering was exempt under Section 4(a)(2) of the Securities Act."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-034949","json":"https://secwatch.observer/filing/0001437749-23-034949.json","markdown":"https://secwatch.observer/filing/0001437749-23-034949.md","text":"https://secwatch.observer/filing/0001437749-23-034949.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1091596/000143774923034949/0001437749-23-034949-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1091596/000143774923034949/aurx20231219c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:43:24.516928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"541cfa465ba21b3dcd725fa520b8f7e9a2c0a395","claim":"Nuo Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at $962,500 (effective 2023-12-18).","evidence_excerpt":"On December 18, 2023, Nuo Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement, dated as of December 8, 2023, with certain accredited investors for the sale of 1,925,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at a price of $0.50 per share for gross proceeds of $962,500 (the “Private Placement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774923034949/0001437749-23-034949-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"$962,500"},{"label":"Effective","value":"2023-12-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}